Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Pharmacy · PA · Hematology, Oncology, PharmacyMedium impact

08.02.30a, Imetelstat (Rytelo®)

Act
by Jun 29, 2026
Effective date
Jun 29, 2026
Identified
Jun 30, 2026

Summary

Independence Blue Cross deleted coverage criteria for imetelstat (Rytelo®) in patients with del(5q) myelodysplastic syndrome and revised coverage criteria for patients without del(5q) disease. The policy now requires specific treatment sequencing and biomarker thresholds (erythropoietin levels, ring sideroblasts, SF3B1 mutations) before imetelstat is covered. Billing teams must update prior authorization requirements to reflect the deletion of del(5q) coverage and the new treatment pathway requirements effective June 29, 2026.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jun 29, 2026 · 4 steps
01Billing and Prior Authorization teams must update systems to reflect that imetelstat (J0870) is NO LONGER covered for patients with del(5q) myelodysplastic syndrome.
02Update PA templates and denial logic to reject claims for del(5q) patients.
03For non-del(5q) patients, update PA requirements to enforce the new treatment sequencing criteria including: (1) confirmation of transfusion-dependent anemia (≥4 RBC units in 8 weeks, pretransfusion Hgb ≤9.0 g/dL), (2) IPSS-R score for lower-risk disease, (3) ring sideroblast percentage and SF3B1 mutation status, and (4) documented treatment failure or relapse on prior ESA, luspatercept-aamt, G-CSF, lenalidomide, or IST as applicable.
04Train billing staff to request and verify serum erythropoietin levels (≤500 or >500 mU/mL threshold) and treatment history before submitting claims.
If missed: Failure to implement these changes will result in claim denials for del(5q) patients and improper authorization for non-del(5q) patients not meeting the revised treatment pathway requirements.

Codes mentioned

J0870

Original notice

08.02.30a, Imetelstat (Rytelo®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.177a, Imetelstat (Rytelo®)MediumEffective Jun 29, 2026 · PharmacyMA08.177, Imetelstat (Rytelo™)MediumEffective May 19, 2025 · Pharmacy08.02.30, Imetelstat (Rytelo™)MediumEffective May 19, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesPA policy changesHematologyOncologyPharmacyCode J0870

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account